Table 1.
Baseline characteristics of patients with different H-FABP levels
| Variables | Total (N = 4594) | Tertile 1 (N = 1685) | Tertile 2 (N = 1452) | Tertile 3 (N = 1457) | p value for trend |
|---|---|---|---|---|---|
| Baseline characteristics | |||||
| Age (years) | 58.2 ± 9.9 | 54.7 ± 9.1 | 58.4 ± 9.2 | 62.0 ± 9.7 | < 0.001 |
| Male (n, %) | 3266 (71.9%) | 1206 (71.6%) | 1041 (71.7%) | 1019 (69.9%) | 0.499 |
| BMI (kg/m2) | 25.92 ± 3.14 | 25.82 ± 2.98 | 25.91 ± 3.08 | 26.06 ± 3.36 | 0.114 |
| Hypertension (n, %) | 3005 (65.4%) | 1041 (61.8%) | 917 (63.2%) | 1047 (71.9%) | < 0.001 |
| Dyslipidemia (n, %) | 4147 (90.3%) | 1520 (90.2%) | 1323 (91.1%) | 1304 (89.5%) | 0.337 |
| Diabetes (n, %) | 1889 (41.1%) | 618 (36.7%) | 566 (39.0%) | 705 (48.4%) | < 0.001 |
| Current smokers (n, %) | 1438 (31.3%) | 548 (32.5%) | 468 (32.2%) | 422 (29.0%) | 0.065 |
| Peripheral vascular disease (n, %) | 59 (1.3%) | 16 (0.9%) | 19 (1.3%) | 24 (1.6%) | 0.222 |
| Cerebrovascular disease (n, %) | 145 (3.2%) | 44 (2.6%) | 46 (3.2%) | 55 (3.8%) | 0.177 |
| Family history of CAD (n, %) | 643 (14.0%) | 258 (15.3%) | 198 (13.6%) | 187 (12.8%) | 0.122 |
| Laboratory data | |||||
| Triglyceride (mmol/L) | 1.80 ± 1.23 | 1.82 ± 1.32 | 1.80 ± 1.15 | 1.78 ± 1.22 | 0.581 |
| TC (mmol/L) | 4.14 ± 1.17 | 4.15 ± 1.20 | 4.13 ± 1.09 | 4.14 ± 1.20 | 0.929 |
| LDL-C (mmol/L) | 2.51 ± 0.99 | 2.53 ± 1.08 | 2.51 ± 0.93 | 2.48 ± 0.95 | 0.260 |
| HDL-C (mmol/L) | 1.05 ± 0.29 | 1.05 ± 0.29 | 1.06 ± 0.29 | 1.06 ± 0.29 | 0.506 |
| Glucose (mmol/L) | 6.20 ± 2.04 | 6.12 ± 2.00 | 6.16 ± 1.99 | 6.33 ± 2.13 | 0.016 |
| HbA1c (%) | 6.54 ± 1.24 | 6.42 ± 1.22 | 6.50 ± 1.17 | 6.72 ± 1.30 | < 0.001 |
| Creatinine (μmol/L) | 77.97 ± 17.30 | 74.17 ± 13.98 | 76.23 ± 14.62 | 84.10 ± 21.16 | < 0.001 |
| eGFR (mL/min/1.73 m2) | 93.74 ± 9.12 | 97.38 ± 8.07 | 94.09 ± 8.09 | 89.16 ± 9.24 | < 0.001 |
| Treatments in hospital | |||||
| Aspirin (n, %) | 4462 (97.1%) | 1637 (97.2%) | 1410 (97.1%) | 1415 (97.1%) | 0.997 |
| β-Blokers (n, %) | 3417 (78.3%) | 1335 (79.2%) | 1133 (78.0%) | 1129 (77.5%) | 0.477 |
| Lipid-lowering mediation (n, %) | 4269 (92.9%) | 1551 (92.0%) | 1348 (92.8%) | 1370 (94.0%) | 0.096 |
| ACEI or ARB (n, %) | 2157 (47.0%) | 714 (42.4%) | 669 (46.1%) | 774 (53.1%) | < 0.001 |
| Gensini score | 34.50 ± 32.07 | 32.42 ± 30.33 | 33.70 ± 30.44 | 37.72 ± 35.24 | < 0.001 |
| Events (n, %) | 380 (8.3%) | 100 (5.9%) | 121 (8.3%) | 159 (10.9%) | < 0.001 |
Values are expressed as the mean ± SD or n (%). Italic values indicate statistical significance
CAD coronary artery disease, BMI body mass index, NGR normal glucose regulation, Pre-DM pre-diabetes mellitus, DM diabetes mellitus, TC total cholesterol, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, HbA1c glycated hemoglobin A1c, H-FABP heart-fatty acid binding protein, ACEI angiotensin converting enzyme inhibitors, ARB angiotensin receptor blocker, eGFR estimated glomerular filtration rate